Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Hughes

Showing results (71-80 of 146) with videos related to

Pageof 15
Sort By:
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Transplantation|April 16, 2004
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantationCharles Mullighan, Sue Heatley, Kathleen Doherty, et al.
Seminars in Musculoskeletal Radiology|October 14, 2008
Magnetic resonance imaging of the hip at 3 Tesla: clinical value in femoroacetabular impingement of the hip and current conceptsTallal Charles Mamisch, Bernd Bittersohl, Timothy Hughes, et al.
Nucleic Acids Research|April 6, 2017
An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusionKatherine M Collins, Yaroslav A Kainov, Evangelos Christodolou, et al.
Muscle & Nerve|August 12, 2015
Twenty-year follow-up of newborn screening for patients with muscular dystrophyJeffrey Chung, Andrea L Smith, Sarah C Hughes, et al.
Investigative Radiology|August 19, 2008
In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilageGoetz H Welsch, Tallal C Mamisch, Timothy Hughes, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Brain, Behavior, and Immunity|February 29, 2020
Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cellsIbrahim A Akkouh, Thor Ueland, Lars Hansson, et al.
Genes & Development|October 17, 2007
Assembly factors Rpf2 and Rrs1 recruit 5S rRNA and ribosomal proteins rpL5 and rpL11 into nascent ribosomesJingyu Zhang, Piyanun Harnpicharnchai, Jelena Jakovljevic, et al.
Blood|September 1, 2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityDeborah L White, Verity A Saunders, Phuong Dang, et al.
Pageof 15

Showing results (71-80 of 146) with videos related to

Sort By:
Pageof 15
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Transplantation|April 16, 2004
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantationCharles Mullighan, Sue Heatley, Kathleen Doherty, et al.
Seminars in Musculoskeletal Radiology|October 14, 2008
Magnetic resonance imaging of the hip at 3 Tesla: clinical value in femoroacetabular impingement of the hip and current conceptsTallal Charles Mamisch, Bernd Bittersohl, Timothy Hughes, et al.
Nucleic Acids Research|April 6, 2017
An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusionKatherine M Collins, Yaroslav A Kainov, Evangelos Christodolou, et al.
Muscle & Nerve|August 12, 2015
Twenty-year follow-up of newborn screening for patients with muscular dystrophyJeffrey Chung, Andrea L Smith, Sarah C Hughes, et al.
Investigative Radiology|August 19, 2008
In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilageGoetz H Welsch, Tallal C Mamisch, Timothy Hughes, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Brain, Behavior, and Immunity|February 29, 2020
Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cellsIbrahim A Akkouh, Thor Ueland, Lars Hansson, et al.
Genes & Development|October 17, 2007
Assembly factors Rpf2 and Rrs1 recruit 5S rRNA and ribosomal proteins rpL5 and rpL11 into nascent ribosomesJingyu Zhang, Piyanun Harnpicharnchai, Jelena Jakovljevic, et al.
Blood|September 1, 2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityDeborah L White, Verity A Saunders, Phuong Dang, et al.
Pageof 15